ReviewAlzheimer's & dementia : the journal of the Alzheimer's Association2022
FRONTotemporal dementia Incidence European Research Study-FRONTIERS: Rationale and design.
Review in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Noninvasive Brain Stimulation in Primary Progressive Aphasia with and Without Concomitant Speech and Language Therapy: Systematic Review and Meta-analysis.Neuropsychology review · 2025Pooled it
- Incidence and Survival Rates of Frontotemporal Lobar Degeneration: Population-Based Registry Study.Neurology · 2026Article
- Survival and mortality rates in early onset dementia.Journal of neurology, neurosurgery, and psychiatry · 2026Article
- Family Caregivers' Experiences With Follow-Up Healthcare for Frontotemporal Dementia: A Narrative Inquiry.Scandinavian journal of caring sciences · 2025Article
- Predictors of Care Home Admission and Survival Rate in Patients With Syndromes Associated With Frontotemporal Lobar Degeneration in Europe.Neurology · 2024Observational
- Genetic forms of tauopathies: inherited causes and implications of Alzheimer's disease-like TAU pathology in primary and secondary tauopathies.Journal of neurology · 2024Review
- A Multimodal Approach for Clinical Diagnosis and Treatment of Primary Progressive Aphasia (MAINSTREAM): A Study Protocol.Brain sciences · 2023Article
- A Review on Music Interventions for Frontotemporal Aphasia and a Proposal for Alternative Treatments.Biomedicines · 2022Review
- Tauopathies: new perspectives and challenges.Molecular neurodegeneration · 2022Review
- FRONTotemporal dementia Incidence European Research Study-FRONTIERS: Rationale and design.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2022Review
- Descriptive Epidemiology of Neurodegenerative Diseases: What Are the Critical Questions?Neuroepidemiology · 2022Article
- Incidence of young-onset dementia in Italy: The Brescia register study.Alzheimer's & dementia (Amsterdam, Netherlands)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
introductionThe incidence of Frontotemporal Lobar Degeneration (FTLD)-related disorders and their characteristics are not well known. The "FRONTotemporal dementia Incidence European Research Study" (FRONTIERS) is designed to fill this gap.
methodsFRONTIERS is a European prospective, observational population study based on multinational registries. FRONTIERS comprises 11 tertiary referral centers across Europe with long-lasting experience in FTLD-related disorders and comprehensive regional referral networks, enabling incidence estimation over well-defined geographical areas. ENDPOINTS: The primary endpoints are (1) the incidence of FTLD-related disorders across Europe; (2) geographic trends of FTLD-related disorders; (3) the distribution of FTLD phenotypes in different populations and ethnicities in Europe; (4) inheritance of FTLD-related disorders, including the frequencies of monogenic FTLD as compared to overall disease burden; and (5) implementation of data banking for clinical and biological material. EXPECTED IMPACTS: FRONTIERS will improve the understanding of FTLD-related disorders and their epidemiology, promoting appropriate public health service policies and treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.